Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment (Drugs, Surgery, Oxygen Therapy, and Others), By Drug Class (Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, and Others) By Disease Type (Chronic Bronchitis and Emphysema), By End Users (Hospitals, Clinics, Homecare, Others) and Region Forecast 2020-2031

Chronic Obstructive Pulmonary Disease (COPD) Market size was valued at US$ 22.2 billion in 2024 and is expected to reach US$ 30.8 billion by 2031, growing at a significant CAGR of 4.8% from 2025-2031. Chronic obstructive pulmonary disease (COPD) is a type of progressive lung disease characterized by long-term respiratory symptoms and airflow limitation, including symptoms such as shortness of breath and a cough, and the causes include tobacco smoking, air pollution, and genetics. Based on the drug class, the combination therapy segment is anticipated to dominate the market share over the forecast period.

According to the World Health Organization, COPD is the third leading cause of death worldwide, causing 3.23 million deaths in 2019. The increasing incidences of respiratory disorders and growing awareness will act as the market growth driver, whereas, the high cost of treatment would be the lagging factor for the market. The rise in the market demand for novel drug therapies and an increase in investments by key market players are opportunities for the expansion of the market. 

Key Developments

• In Oct 2021, Mylan Pharmaceuticals received FDA approval for its investigational new drug application for Breyna (Budesonide and Formoterol fumarate dihydrate inhalation aerosol), for the treatment of asthma and COPD.
• In April 2022, GSK launched Trelegy Ellipta, a single-inhaler triple therapy for COPD patients.